自我穴位按压治疗过敏性鼻炎:随机、单盲、非特异性对照、平行试验的研究方案
过敏性鼻炎(AR)现有常规疗法不尽人意,针灸被新版临床实践指南推荐为对非药物治疗感兴趣患者的选择之一。本试验为随机、单盲、非特异性对照、两臂平行临床试验,含2周导入期、4周干预期和8周随访期,受试者随机分为特异性穴位按压组或非特异性穴位按压组,每日两次、每穴1分钟、持续4周,评估症状严重程度7分量表、鼻结膜炎生活质量问卷(RQLQs)、缓解药物评分及不良事件等。
要点
- 试验比较特异性穴位与非特异性穴位自我按压对过敏性鼻炎的疗效与安全性。
- 干预为每日两次、每穴1分钟、持续4周,随访8周。
- 结局包括症状严重程度7分量表、RQLQs、缓解药物评分和不良事件。
核心结论
- 本研究结果应为自我穴位按压治疗过敏性鼻炎的疗效和安全性提供科学证据。
- 本研究可能有助于为过敏性鼻炎患者开发一种低成本、非侵入性的自我管理方法。
研究设计与样本
- 随机、单盲、非特异性对照、两臂平行临床试验,含2周导入期、4周干预期和8周随访期。
- 符合条件参与者随机分入特异性穴位按压组或非特异性穴位按压组。
- 受试者在五个特异性穴位或五个非特异性穴位上自我按压,每穴1分钟,每日两次,持续4周。
关键数值与推荐
- 结局指标包括症状严重程度7分量表、鼻结膜炎生活质量问卷标准化活动版(RQLQs)、缓解药物评分、不良事件及受试者对研究的看法。
- 数据使用社会科学统计软件包(SPSS)以卡方检验或t检验分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出现有证据受高偏倚风险和方法学异质性影响而受限。
- 原文指出需要严格设计的随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Allergic rhinitis (AR) is an IgE-mediated inflammatory disease. Current conventional therapies for AR are unsatisfactory. Acupuncture has been recommended as an optional treatment for AR patients who are interested in non-pharmacotherapy in the new clinical practice guidelines for AR. Acupressure is a sub-type of acupuncture which is non-invasive with a low risk and can be self-administered. However, the current limited evidence is compromised by the high risk of bias and heterogeneity of methodology. Therefore, rigorously designed randomized controlled trials (RCTs) are needed. This proposed RCT aims to evaluate the efficacy and safety of self-administered acupressure for the management of AR. METHODS/DESIGN: We have designed a randomized, single-blind, non-specific controlled, two-arm, parallel clinical trial involving a 2-week run-in period, a 4-week intervention period and an 8-week follow-up period. The eligible participants will be randomized into either a specific or a non-specific acupressure group. They will be required to perform self-administered acupressure on either five specific acupressure points or five non-specific acupressure points, 1 min for each point, twice a day for 4 weeks. Participants will be asked to complete self-administered questionnaires for outcome measures including a 7-point scale of symptom severity, the Rhinoconjunctivitis Quality of Life Questionnaire with Standardized Activities (RQLQs), relief medication scores, adverse events and participants' opinion of this study at the different assessment points throughout the trial period. Data will be analyzed by the chi-square or t test using Statistical Package for Social Science (SPSS) software. DISCUSSION: The findings from this study should provide scientific evidence for the efficacy and safety of self-administered acupressure for the management of AR. This study may assist the development of a non-cost, non-invasive self-management method for AR sufferers. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry (ANZCTR), ID: ACTRN12617001106325 Registered on 28 July 2017.
引用
- Liang Y, Lenon GB, Yang AWH, et al. Self-administered acupressure for allergic rhinitis: study protocol for a randomized, single-blind, non-specific controlled, parallel trial. Trials. 2019. PMID: 31238972. doi:10.1186/s13063-019-3495-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。